Drug Profile
Research programme: respiratory disease therapeutics - Respiratorius
Alternative Names: LISA; RCD-007Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Respiratorius
- Class Anti-inflammatories; Bronchodilators
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 20 May 2021 Respiratory disease therapeutics is still in Preclinical trials for Chronic obstructive pulmonary disease in Sweden
- 20 May 2021 Respiratory disease therapeutics is still in Preclinical trials for Asthma in Sweden
- 31 Dec 2018 Respiratorius has pending patent protection application for RES9000 series of compounds